Report
Debbie Wang
EUR 147.86 For Business Accounts Only

Boston Scientific's Strong Second Quarter Exceeds Our Expectations

Boston Scientific displayed great strength in the second quarter thanks to its lineup of new products and commercial execution; we anticipate moderately increasing our fair value estimate after incorporating more optimistic expectations for top-line growth through the midterm. While we think it is unlikely that Boston can sustain this quarter’s 10% organic growth, we do think it is reasonable to boost our estimate for average annual top-line growth through 2020 to 6%, up from 5%. We’re leaving B...
Underlying
BOSTON SCIENTIFIC CORPORATION

Boston Scientific develops, manufactures and markets medical devices. The company's Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. The company's Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Debbie Wang

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch